アクセス数 : ?
ダウンロード数 : ?
ID 115284
著者
板東, 浩 Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN研究者をさがす
キーワード
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Phlorizin
Antihypertensive Agents (AHA)
Cardiovascular Event
Blood Pressure
資料タイプ
学術雑誌論文
抄録
Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) has been in focus for the pharmacotherapy of diabetes. SGLT2i contributes to decreasing blood pressure (BP) to some degree. BP changes were analyzed in 4 well-known mega-studies. They are Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58. The ultimate goal of antihypertensive and hypoglycemic agents is not the achievement of target values, but the suppression of cardiovascular events. SGLT-2i show excellent strategy for event suppression and adjunct method for hypertension.
掲載誌名
Asploro Journal of Biomedical and Clinical Case Reports
ISSN
25820370
出版者
Asploro
3
3
開始ページ
186
終了ページ
190
発行日
2020-08-28
権利情報
© 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系